These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16274829)
1. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H J Control Release; 2006 Jan; 110(2):347-352. PubMed ID: 16274829 [TBL] [Abstract][Full Text] [Related]
2. Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds. Takatsuka S; Morita T; Horikiri Y; Yamahara H; Saji H Int J Pharm; 2008 Feb; 349(1-2):94-100. PubMed ID: 17869034 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Takatsuka S; Kitazawa T; Morita T; Horikiri Y; Yoshino H Eur J Pharm Biopharm; 2006 Jan; 62(1):52-8. PubMed ID: 16289777 [TBL] [Abstract][Full Text] [Related]
4. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Takatsuka S; Morita T; Koguchi A; Horikiri Y; Yamahara H; Yoshino H Int J Pharm; 2006 Jun; 316(1-2):124-30. PubMed ID: 16600541 [TBL] [Abstract][Full Text] [Related]
5. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H J Control Release; 2006 Oct; 115(2):183-8. PubMed ID: 16989920 [TBL] [Abstract][Full Text] [Related]
6. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. Natsume H; Iwata S; Ohtake K; Miyamoto M; Yamaguchi M; Hosoya K; Kobayashi D; Sugibayashi K; Morimoto Y Int J Pharm; 1999 Aug; 185(1):1-12. PubMed ID: 10425360 [TBL] [Abstract][Full Text] [Related]
7. Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant. Takatsuka S; Morita T; Horikiri Y; Yamahara H; Saji H Int J Pharm; 2007 Jun; 338(1-2):87-93. PubMed ID: 17317052 [TBL] [Abstract][Full Text] [Related]
8. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats. Dong Z; Katsumi H; Sakane T; Yamamoto A Int J Pharm; 2010 Jun; 393(1-2):244-52. PubMed ID: 20417700 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique. Hosoya K; Kubo H; Natsume H; Sugibayashi K; Morimoto Y Biol Pharm Bull; 1994 Feb; 17(2):316-22. PubMed ID: 7515747 [TBL] [Abstract][Full Text] [Related]
10. Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption. Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H J Control Release; 2007 Jul; 120(1-2):88-94. PubMed ID: 17512076 [TBL] [Abstract][Full Text] [Related]
11. Improved nasal absorption of drugs using poly-L-arginine: effects of concentration and molecular weight of poly-L-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats. Miyamoto M; Natsume H; Iwata S; Ohtake K; Yamaguchi M; Kobayashi D; Sugibayashi K; Yamashina M; Morimoto Y Eur J Pharm Biopharm; 2001 Jul; 52(1):21-30. PubMed ID: 11438420 [TBL] [Abstract][Full Text] [Related]
12. Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats. Ohtake K; Natsume H; Ueda H; Morimoto Y J Control Release; 2002 Aug; 82(2-3):263-75. PubMed ID: 12175742 [TBL] [Abstract][Full Text] [Related]
13. Enhancement potential of sucrose laurate (L-1695) on intestinal absorption of water-soluble high molecular weight compounds. Onishi H; Imura Y; Uchida M; Machida Y Curr Drug Deliv; 2012 Sep; 9(5):487-94. PubMed ID: 22520068 [TBL] [Abstract][Full Text] [Related]
14. Absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs including peptide and protein drugs in rats. Alama T; Kusamori K; Katsumi H; Sakane T; Yamamoto A Int J Pharm; 2016 Feb; 499(1-2):58-66. PubMed ID: 26707414 [TBL] [Abstract][Full Text] [Related]
15. Aminated gelatin as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. Wang J; Sakai S; Deguchi Y; Bi D; Tabata Y; Morimoto K J Pharm Pharmacol; 2002 Feb; 54(2):181-8. PubMed ID: 11848281 [TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine inhibits Na+ absorption across human nasal epithelial cells. Rochat T; Lacroix JS; Jornot L J Cell Physiol; 2004 Oct; 201(1):106-16. PubMed ID: 15281093 [TBL] [Abstract][Full Text] [Related]
17. Improvement of pulmonary absorptions of poorly absorbable drugs using Gelucire 44/14 as an absorption enhancer. Zhang H; Huang X; Mi J; Huo Y; Wang G; Xing J; Gao Y J Pharm Pharmacol; 2014 Oct; 66(10):1410-20. PubMed ID: 24849123 [TBL] [Abstract][Full Text] [Related]
18. Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Miyamoto M; Natsume H; Satoh I; Ohtake K; Yamaguchi M; Kobayashi D; Sugibayashi K; Morimoto Y Int J Pharm; 2001 Sep; 226(1-2):127-38. PubMed ID: 11532576 [TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats. Maeda T; Miyazono Y; Ito K; Hamada K; Sekine S; Horie T Cancer Chemother Pharmacol; 2010 May; 65(6):1117-23. PubMed ID: 19756603 [TBL] [Abstract][Full Text] [Related]
20. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Marttin E; Verhoef JC; Cullander C; Romeijn SG; Nagelkerke JF; Merkus FW Pharm Res; 1997 May; 14(5):631-7. PubMed ID: 9165535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]